WO2000000156A3 - Methods for modulating immunological responses by targeting antigen to apcs in conjuction with anti-cd40 ligands - Google Patents

Methods for modulating immunological responses by targeting antigen to apcs in conjuction with anti-cd40 ligands Download PDF

Info

Publication number
WO2000000156A3
WO2000000156A3 PCT/US1999/012825 US9912825W WO0000156A3 WO 2000000156 A3 WO2000000156 A3 WO 2000000156A3 US 9912825 W US9912825 W US 9912825W WO 0000156 A3 WO0000156 A3 WO 0000156A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
antigen
treatment
antibody
compositions
Prior art date
Application number
PCT/US1999/012825
Other languages
French (fr)
Other versions
WO2000000156A2 (en
Inventor
William F Wade
Douglas Demian
Original Assignee
Dartmouth College
William F Wade
Douglas Demian
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dartmouth College, William F Wade, Douglas Demian filed Critical Dartmouth College
Priority to AU49548/99A priority Critical patent/AU4954899A/en
Publication of WO2000000156A2 publication Critical patent/WO2000000156A2/en
Publication of WO2000000156A3 publication Critical patent/WO2000000156A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Methods and compositions are provided which upon administration to a subject in need of such treatment result in enhanced or suppressed immunological responses and in particular enhanced or suppressed humoral (antibody) immune responses to a desired antigen. These methods and compositions include an antigen directly or indirectly attached to an antibody specific for antigen expressed by an antigen-presenting cell and optionally an anti-CD40 antibody. These methods and compositions are particularly useful in the treatment of infectious diseases, such as viral, bacterial or fungal infection, and the treatment and/or prevention of cancer, especially for treatment of aged individuals or other subjects having impaired immune systems, and the treatment of autoimmune diseases, transplant, allergy, inflammatory diseases, wherein suppression of antigen-specific immune response is therapeutically beneficial.
PCT/US1999/012825 1998-06-26 1999-06-25 Methods for modulating immunological responses by targeting antigen to apcs in conjuction with anti-cd40 ligands WO2000000156A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU49548/99A AU4954899A (en) 1998-06-26 1999-06-25 Methods and compositions for modulating antigen-specific immunological (humoral)responses by targeting such antigen to apcs in conjunction with anti-cd40 ligan d administration

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9084998P 1998-06-26 1998-06-26
US60/090,849 1998-06-26

Publications (2)

Publication Number Publication Date
WO2000000156A2 WO2000000156A2 (en) 2000-01-06
WO2000000156A3 true WO2000000156A3 (en) 2007-08-16

Family

ID=22224621

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/012825 WO2000000156A2 (en) 1998-06-26 1999-06-25 Methods for modulating immunological responses by targeting antigen to apcs in conjuction with anti-cd40 ligands

Country Status (2)

Country Link
AU (1) AU4954899A (en)
WO (1) WO2000000156A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7063845B2 (en) 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
WO2001083755A2 (en) * 2000-04-28 2001-11-08 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
IL152652A0 (en) 2000-05-08 2003-06-24 Medarex Inc Human monoclonal antibodies to dendritic cells
US7560534B2 (en) 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
CA2658221C (en) 2001-04-27 2012-11-27 Kyowa Hakko Kirin Co., Ltd. Anti-cd40 monoclonal antibody
US9809654B2 (en) 2002-09-27 2017-11-07 Vaccinex, Inc. Targeted CD1d molecules
US20040146948A1 (en) * 2002-10-18 2004-07-29 Centenary Institute Of Cancer Medicine And Cell Biology Compositions and methods for targeting antigen-presenting cells with antibody single-chain variable region fragments
US9259459B2 (en) 2003-01-31 2016-02-16 Celldex Therapeutics Inc. Antibody vaccine conjugates and uses therefor
EP1594533B1 (en) 2003-01-31 2012-04-11 Celldex Research Corporation Antibody vaccine conjugates and uses therefor
EP2112930B1 (en) 2007-02-21 2017-01-11 Vaccinex, Inc. Modulation of nkt cell activity with antigen-loaded cdid molecules
ES2445755T3 (en) 2007-11-07 2014-03-05 Celldex Therapeutics, Inc. Antibodies that bind human dendritic and epithelial cells 205 (DEC-205)
JP5984388B2 (en) * 2008-07-16 2016-09-06 ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ HIV vaccine based on targeting maximum GAG and NEF to dendritic cells
US9139809B2 (en) 2009-01-08 2015-09-22 Albert Einstein College Of Medicine Of Yeshiva University Bacterial vaccines with cell wall-associated ceramide-like glycolipids and uses thereof
CA2754764A1 (en) 2009-03-10 2010-09-16 Baylor Research Institute Antigen presenting cell targeted cancer vaccines
ES2635080T3 (en) * 2009-03-10 2017-10-02 Baylor Research Institute Cancer vaccines targeting antigen presenting cells
FR2955773B1 (en) 2010-02-01 2017-05-26 Commissariat A L'energie Atomique MOLECULAR COMPLEX FOR TARGETING ANTIGENS TO ANTIGEN-PRESENTING CELLS AND ITS APPLICATIONS FOR VACCINATION
US9371352B2 (en) 2013-02-08 2016-06-21 Vaccinex, Inc. Modified glycolipids and methods of making and using the same
CN106103483A (en) 2014-01-13 2016-11-09 贝勒研究院 The novel vaccine of the related disease of anti-HPV with HPV
US10610585B2 (en) 2017-09-26 2020-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating and preventing HIV

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204449A (en) * 1988-01-12 1993-04-20 Bunge (Australia) Pty. Ltd. Antigen antibody conjugate for major histocompatibility complex (MHC) class I or II antigens
US5247069A (en) * 1986-06-13 1993-09-21 Oncogen Ligands and methods for augmenting B-cell proliferation
US5637481A (en) * 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5693780A (en) * 1991-07-25 1997-12-02 Idec Pharmaceuticals Corporation Recombinant antibodies for human therapy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5247069A (en) * 1986-06-13 1993-09-21 Oncogen Ligands and methods for augmenting B-cell proliferation
US5204449A (en) * 1988-01-12 1993-04-20 Bunge (Australia) Pty. Ltd. Antigen antibody conjugate for major histocompatibility complex (MHC) class I or II antigens
US5693780A (en) * 1991-07-25 1997-12-02 Idec Pharmaceuticals Corporation Recombinant antibodies for human therapy
US5637481A (en) * 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell

Also Published As

Publication number Publication date
AU4954899A (en) 2000-01-17
WO2000000156A2 (en) 2000-01-06

Similar Documents

Publication Publication Date Title
WO2000000156A3 (en) Methods for modulating immunological responses by targeting antigen to apcs in conjuction with anti-cd40 ligands
Bulut et al. Overcoming immune dysfunction in the elderly: trained immunity as a novel approach
Kamath et al. Synchronization of dendritic cell activation and antigen exposure is required for the induction of Th1/Th17 responses
PT900380E (en) METHODS FOR SELECTING AND PRODUCING PEPTIDIC EPITHOPES OF T-CELLS AND VACCINES INCORPORATING THE REFERRED EPITHOPES SELECTED
GEP20053658B (en) Soluble CTLA4 Mutant Molecules and Uses Thereof
AUPN015794A0 (en) Variants of human papilloma virus antigens
EP1246644A4 (en) Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
WO1999041383A8 (en) Antigen library immunization
AU2953895A (en) Multi-stage cascade boosting vaccine
AU2002347369A1 (en) Immunotherapeutic methods and systems
WO2004091543A3 (en) Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells
WO1999064464A3 (en) Method for producing or enhancing a t-cell response against a target cell using a complex comprising an hla class i molecule and an attaching means
WO2000023955A8 (en) Virus-like particles for the induction of autoantibodies
AU7392296A (en) Dendritic cell stimulatory factor
EP1385541A4 (en) Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and qs-21
CA2232344A1 (en) Compositions and methods for enhancing immune responses mediated by antigen-presenting cells
WO2000062657A3 (en) Improvement of t cell mediated immunity
WO2005028496A3 (en) Vaccine for treatment and prevention of herpes simplex virus infection
WO2000067788A3 (en) Use of soluble costimulatory molecules to enhance immune responses
NZ505834A (en) Compositions containing polypeptides isolated from mycobacterium vaccae and methods for their use
WO2004044155A3 (en) MIP-1α AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE
WO2003092615A3 (en) Use of anti-cd1 antibodies for the modulation of immune responses
WO1999017787A3 (en) Use of a chemically-stabilized chlorite solution for inhibiting an antigen-specific immune response
WO2002034287A3 (en) Therapeutic vaccine formulations containing chitosan
EP2174665A3 (en) Compositions and methods for activating innate and allergic immunity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 09720078

Country of ref document: US

122 Ep: pct application non-entry in european phase